PAPER Oskarsson B, Mauricio EA, Shah JS, Li Z, Rogawski MA
PAPER Akushevich I, Yashkin AP, Yashin AI, Kravchenko J34009643
PAPER Coughlan G, Larsen R, Kim M, White D, Gillings R, Irvine M, Scholey A, Cohen N, Legido-Quigley C, Hornberger M, Minihane AM
APOE ε4 alters associations between docosahexaenoic acid and preclinical markers of Alzheimer's disease.Brain Commun. 2021;3(2):fcab085. Epub 2021 May 11 PubMed: 34007965
PAPER Van Harten AC, Phatnani H, Przedborski S34006386
PAPER Powell DS, Oh ES, Lin FR, Deal JA34008037
Genentech IncSan Mateo, United States
RESEARCH NEWS 2021-05-20 Research News Part 1 of two Alzheimer’s disease and Down’s syndrome are closely related through their β-amyloidosis pathology. Alas, despite dozens of anti-amyloid clinical trials in AD over the past 20 years, there has been but one in Down's, a more ...
Queen’s UniversityKingston, Canada
University of Massachusetts Medical School WorcesterBoston, United States
Carol Colton, James Burke, W. Kirby Gottschalk, Michael Vitek, David A. Wink on Polyamines–What Role in Neurodegeneration?
COMMENT Immuno-Metabolism of Arginine as a Target for AD We were the first to show increased Arginase-1 (Arg-1) expression in AD brains as part of a larger investigation into an alternative immune activation phenotype in early stages of AD that affects arginine ...
Oligomerix, Inc.Bronx, United States
COMMENT Great historical perspective! sambak 0 ...
COMMENT Understanding the role of the isotype in developing antibody therapies for Alzheimer’s disease is indeed critical. The work from our group also supports the use of tau antibodies in an IgG4 (low effector function) isotype in clinical trials. In a direct ...
Studies and reseachParis, France